Providers

Provider Resource Center

Research

Advancing Treatment-Resistant Depression Therapy: A Randomized, Placebo-Controlled, Triple-Masked Clinical Trial on IV Ketamine

In a pioneering clinical trial, researchers are delving into the potential of ketamine as a rapid-acting antidepressant for treatment-resistant major depressive disorder (MDD). Unlike traditional MDD treatments, which can take weeks or months to show results, ketamine, a well-known NMDA receptor antagonist used in anesthesia, is being tested for its ability to provide swift relief from severe mood disorders. The study contrasts the effects of ketamine with those of midazolam, a similar anesthetic without antidepressant properties, acting as an active control. Spanning up to eight weeks, this trial includes two overnight stays in a specialized research facility, marking a significant step in the quest for faster and more effective MDD treatments.

Financial Services

Manage your account or make a payment.

Disclaimers

Financing Disclaimer: $325/month for Uplift Momentum Protocol™ (medical procedure), financed over 12 months with a total cost of $3,900, 0% interest. Approval based on internal criteria, including bank account history and a soft credit pull. Payments are auto-withdrawn monthly . Subject to $25 late fee for missed payments and other terms. Cancellation within 3 days of agreement allowed. Governed by California law and AAA arbitration rules. View Terms & Conditions

Important Medical Disclaimers

Individuals showcased on KetamineUplift.com are actors, the content is not reflective of their thoughts, views, or perspectives.

Patients

Home
Science
Experience
Program
About
FAQ's
Financial Services
Contact

Providers

Provider Home
Practice Info
Resources
Research
Patient Referrals
Schedule Tour

Get in touch

(310) 280-4440
care@ketamineuplift.com

4640 Admiralty Way
Suite 718A
Marina del Rey, CA 90292

Directions

© 2024 Ketamine Uplift | Terms of Service | Privacy Policy